- Home
- AZ vs NERV Comparison
AZ vs NERV Comparison
Compare AZ & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | NERV |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.1M | 301.6M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AZ | NERV |
|---|---|---|
| Price | $5.90 | $5.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $15.00 | $10.50 |
| AVG Volume (30 Days) | ★ 391.0K | 127.8K |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $532.60 | N/A |
| Revenue Next Year | $178.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $1.30 |
| 52 Week High | $12.36 | $12.46 |
Technical Indicators
Market Signals| Indicator | AZ | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 37.08 | 32.24 |
| Support Level | $5.09 | $5.02 |
| Resistance Level | $6.93 | $6.69 |
| Average True Range (ATR) | 0.61 | 0.33 |
| MACD | -0.15 | -0.12 |
| Stochastic Oscillator | 31.03 | 2.05 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.